Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 13, 28 - 30 (2007)
doi:10.1038/nm0107-28
A 'good death' for tumor immunology
Walter J Storkus1 & Louis D Falo Jr1
- The authors are in the Departments of Dermatology and Immunology, University of Pittsburgh School of Medicine, W1041 Biomedical Sciences Tower, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA. e-mail: storkuswj@upmc.edu or e-mail: falold@upmc.edu
Abstract
A class of cell-killing chemotherapeutic agents seems to have an additional benefit. The drugs help prompt the immune system to turn against the tumor (pages 54–61).
Findings by Obeid et al.1 in this issue highlight a way to potentially enhance the ability of the immune system to kill tumor cells. The authors suggest that how cells die during chemotherapy is critical; one set of chemotherapeutic agents in particular, anthracyclins, seem to foster a favorable immunogenic environment.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
A 'good death' for tumor immunologyNature Medicine News and Views (01 Jan 2007)
Research HighlightsNature Biotechnology News and Views (01 Jan 2007)
See all 5 matches for News And ViewsRESEARCH
Calreticulin exposure dictates the immunogenicity of cancer cell deathNature Medicine Article (01 Jan 2007)
Calreticulin exposure dictates the immunogenicity of cancer cell deathNature Medicine Article (01 Jan 2007)
See all 3 matches for Research